John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INFI
2051
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $457K | ﹤0.01% |
401,277
-127,093
| -24% | -$152K |
|
2052
Protara Therapeutics
TARA
$235M
| $454K | ﹤0.01% |
88,779
-101,499
| -53% | -$534K |
|
2053
Anterix
ATEX
$1.81B
| $452K | ﹤0.01% |
7,800
-300
| -4% | -$16.4K |
|
|
LITS
2054
Lite Strategy Inc
LITS
$35.7M
| $452K | ﹤0.01% |
37,472
+32,806
| +703% | +$1.29M |
|
2055
SkinHealth Systems
SKIN
$84.6M
| $452K | ﹤0.01% |
+26,764
| New | +$442K |
|
|
VNE
2056
DELISTED
Veoneer, Inc.
VNE
| $452K | ﹤0.01% |
12,230
-100,648
| -89% | -$3.58M |
|
2057
Corteva
CTVA
$55.4B
| $451K | ﹤0.01% |
+7,852
| New | +$401K |
|
2058
Olin
OLN
$1.98B
| $451K | ﹤0.01% |
8,636
-3,646
| -30% | -$186K |
|
|
SWIR
2059
DELISTED
Sierra Wireless
SWIR
| $451K | ﹤0.01% |
25,000
-10,743
| -30% | -$179K |
|
2060
West Bancorporation
WTBA
$486M
| $448K | ﹤0.01% |
16,476
+5,665
| +52% | +$167K |
|
|
ZYXI
2061
DELISTED
Zynex
ZYXI
| $448K | ﹤0.01% |
+71,848
| New | +$505K |
|
|
PCSB
2062
DELISTED
PCSB Financial Corporation
PCSB
| $448K | ﹤0.01% |
23,418
-107
| -0.5% | -$2.03K |
|
2063
EPAM Systems
EPAM
$5.77B
| $445K | ﹤0.01% |
1,500
+447
| +42% | +$175K |
|
2064
Townsquare Media
TSQ
$107M
| $445K | ﹤0.01% |
34,790
-22,038
| -39% | -$270K |
|
|
JNCE
2065
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $442K | ﹤0.01% |
65,138
-253,413
| -80% | -$1.81M |
|
2066
Distribution Solutions Group
DSGR
$1.61B
| $439K | ﹤0.01% |
+22,804
| New | +$496K |
|
2067
Upland Software
UPLD
$13.9M
| $439K | ﹤0.01% |
2,490
-15,575
| -86% | -$2.86M |
|
2068
Aligos Therapeutics
ALGS
$46.6M
| $436K | ﹤0.01% |
8,108
+5,413
| +201% | +$433K |
|
2069
Planet Labs
PL
$7.68B
| $435K | ﹤0.01% |
+85,586
| New | +$472K |
|
2070
AGCO
AGCO
$7.77B
| $434K | ﹤0.01% |
2,974
-89,394
| -97% | -$11.3M |
|
2071
Preformed Line Products
PLPC
$2.02B
| $433K | ﹤0.01% |
+6,833
| New | +$410K |
|
|
LL
2072
DELISTED
LL Flooring Holdings, Inc.
LL
| $432K | ﹤0.01% |
+30,842
| New | +$471K |
|
|
CVLY
2073
DELISTED
Codorus Valley Bancorp Inc
CVLY
| $432K | ﹤0.01% |
19,658
-2,800
| -12% | -$61.6K |
|
|
VNTR
2074
DELISTED
Venator Materials PLC
VNTR
| $432K | ﹤0.01% |
242,742
-163,195
| -40% | -$364K |
|
2075
BGSF Inc
BGSF
$57.7M
| $429K | ﹤0.01% |
32,553
-13,718
| -30% | -$190K |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.